CD274 and melanoma: Examples of checkpoint inhibitors associated to UV1 include: Ipilimumab (anti-CTLA-4) or pembrolizumab (anti-PD-1) in melanoma patients (NCT02275416 and NCT03538314, respectively), and ipilimumab in association with nivolumab (anti-PD-L1) in patients affected by mesothelioma (NCT04300244) or melanoma (NCT04382664).